Where is Ponatinib made?

Ponatinib (Ponatinib) is a drug developed by ARIAD Pharmaceuticals for the treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-target tyrosine kinase inhibitor that causes some forms of chronic myelogenous leukemia, namely those with the T315I mutation, to be resistant to current treatments such as imatinib. Ponatinib has been designed to be effective against these types of tumors.

The U.S. Food and Drug Administration (FDA) approved the drug in December 2012 as a drug candidate with possible risks of life-threatening blood clots and severe narrowing of blood vessels. The FDA approved and updated the label in 2016 to include patients with chronic, accelerated, or blast phase chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia who have no indications for other tyrosine kinase inhibitor treatments. T315I-positive and T315I-positive Philadelphia chromosome-positive acute lymphoblastic leukemia were also approved.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.